Cytokinetics, Incorporated (CYTK)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cytokinetics, Incorporated (CYTK) trades at $70.54 with AI Score 65/100 (Grade B+). Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Market cap: $8.78B, Sector: Healthcare.
Last analyzed: May 10, 2026CYTK stock analysis for 2026: Analysts have set a consensus price target of $90.67 for Cytokinetics, Incorporated, suggesting 28.5% upside from the current price of $70.54. The AI MoonshotScore is 65/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
CYTK: 3/5 perspectives are bullish. Dominant signal: Izzy Englander bullish.
Cytokinetics, Incorporated (CYTK) Healthcare & Pipeline Overview
Cytokinetics, Incorporated is a biopharmaceutical company specializing in muscle biology, developing novel therapies for diseases like heart failure and amyotrophic lateral sclerosis. With a focus on muscle activators and inhibitors, Cytokinetics aims to address unmet needs in cardiovascular and neuromuscular conditions, supported by strategic alliances and ongoing clinical trials.
What Is the Investment Thesis for CYTK?
Cytokinetics presents a notable research candidate based on its late-stage clinical pipeline and focus on muscle biology. The company's lead drug candidate, aficamten, targeting hypertrophic cardiomyopathy, has the potential to generate significant revenue upon successful commercialization. Positive Phase III trial results for aficamten could serve as a major catalyst, driving stock appreciation. However, the company's negative profit margin of -784.0% highlights the risks associated with biopharmaceutical development, including clinical trial failures and regulatory hurdles. Reldesemtiv's success in treating ALS and SMA is also a key value driver. The strategic alliance with Astellas Pharma Inc. provides financial support and expertise, mitigating some development risks.
Based on FMP financials and quantitative analysis
CYTK Key Highlights
- Market capitalization of $8.05 billion reflects investor confidence in Cytokinetics' pipeline and potential for future growth.
- Gross margin of 90.3% indicates strong pricing power and efficient manufacturing processes upon commercialization.
- Beta of 0.48 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- Strategic alliance with Astellas Pharma Inc. provides financial resources and expertise for drug development and commercialization.
- Focus on muscle biology and innovative drug candidates positions Cytokinetics as a leader in addressing unmet needs in cardiovascular and neuromuscular diseases.
Who Are CYTK's Competitors?
CYTK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | $231.29 | -2.07% | $14.51B | 58 |
| AXSM Axsome Therapeutics, Inc. | $255.43 | +0.65% | $13.14B | 68 |
| ABVX Abivax S.A. | $96.55 | -4.28% | 7B | 76 |
| NUVL Nuvalent, Inc. | $123.20 | -0.20% | $9.06B | 48 |
| HALO Halozyme Therapeutics, Inc. | $69.52 | -1.70% | $8.25B | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYTK's Key Strengths?
- Late-stage clinical pipeline with multiple drug candidates.
- Expertise in muscle biology and drug development.
- Strategic alliance with Astellas Pharma Inc.
- Strong gross margin potential upon commercialization.
What Are CYTK's Weaknesses?
- High operating expenses due to ongoing clinical trials.
- Negative profit margin reflecting pre-commercialization stage.
- Reliance on clinical trial success and regulatory approvals.
- Competition from established pharmaceutical companies.
What Could Drive CYTK Stock Higher?
- Phase III clinical trial results for aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
- Potential regulatory approval and commercialization of aficamten.
- Phase III clinical trial of omecamtiv mecarbil in patients with heart failure.
- Development of CK-136, a novel cardiac troponin activator, in Phase I clinical trial.
- Advancement of CK-3772271, a small molecule cardiac myosin inhibitor, through Phase I clinical trial.
What Are the Key Risks for CYTK?
- Clinical trial failures for key drug candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from existing and emerging therapies.
- High operating expenses and negative profit margin.
- Dependence on strategic alliances for funding and expertise.
What Are the Growth Opportunities for CYTK?
- Aficamten for Hypertrophic Cardiomyopathy (HCM): Aficamten, a novel cardiac myosin inhibitor, represents a significant growth opportunity with a large addressable market in symptomatic obstructive HCM. The Phase III clinical trial results are expected to be a major catalyst. Success in this indication could lead to rapid adoption and substantial revenue generation, given the limited treatment options currently available. The market for HCM therapies is projected to reach billions of dollars, offering Cytokinetics a significant share if aficamten proves effective and safe.
- Omecamtiv Mecarbil for Heart Failure: Omecamtiv mecarbil, a cardiac myosin activator, targets a substantial patient population with heart failure. Positive outcomes from the ongoing Phase III clinical trial could lead to regulatory approval and commercialization, addressing a critical unmet need in heart failure management. The global heart failure therapeutics market is estimated to be worth billions, providing a significant revenue opportunity for Cytokinetics. The strategic alliance with Astellas Pharma Inc. further supports the development and commercialization of omecamtiv mecarbil.
- Reldesemtiv for Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA): Reldesemtiv, a skeletal muscle troponin activator, targets ALS and SMA, both debilitating neuromuscular diseases. While previous trials have not met endpoints, further development and potential partnerships could unlock value in these indications. The market for ALS and SMA therapies is growing, driven by increased awareness and advancements in genetic therapies. Cytokinetics' continued research and development efforts in this area could lead to breakthroughs and market entry.
- Expansion of Pipeline with Novel Muscle Activators and Inhibitors: Cytokinetics' ongoing research and development efforts to discover and develop new muscle activators and inhibitors represent a long-term growth opportunity. The company's expertise in muscle biology and drug development positions it to create innovative therapies for a range of muscle-related diseases. Early-stage clinical trials for CK-136 and CK-3772271 could yield promising results, expanding the company's pipeline and future revenue potential.
- Strategic Partnerships and Collaborations: Cytokinetics can leverage strategic partnerships and collaborations to expand its reach and accelerate drug development. Collaborating with other pharmaceutical companies or research institutions can provide access to new technologies, funding, and expertise. The existing alliance with Astellas Pharma Inc. demonstrates the value of such partnerships. Future collaborations could focus on specific therapeutic areas or geographic regions, enhancing Cytokinetics' competitive position and growth prospects.
What Opportunities Does CYTK Have?
- Successful commercialization of aficamten for HCM.
- Expansion of pipeline with new muscle activators and inhibitors.
- Strategic partnerships and collaborations.
- Growing market for muscle-related disease treatments.
What Threats Does CYTK Face?
- Clinical trial failures and regulatory setbacks.
- Competition from existing and emerging therapies.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
What Are CYTK's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in muscle biology and drug development.
- Strategic alliance with Astellas Pharma Inc.
- Late-stage clinical pipeline with potential for near-term revenue generation.
- Focus on addressing unmet needs in cardiovascular and neuromuscular diseases.
What Does CYTK Do?
Cytokinetics, Incorporated, founded in 1997 and headquartered in South San Francisco, California, is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing muscle activators and inhibitors. The company's core focus lies in creating small molecule drug candidates engineered to impact muscle function and contractility, addressing debilitating diseases with significant unmet medical needs. Their pipeline includes a range of drug candidates targeting various conditions, including heart failure, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). Key drug candidates include omecamtiv mecarbil, a cardiac myosin activator in Phase III clinical trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III trials for ALS and SMA. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator in Phase I trials, aficamten, a cardiac myosin inhibitor in Phase III trials for symptomatic obstructive HCM, and CK-3772271, a cardiac myosin inhibitor in Phase I trials. Cytokinetics has a strategic alliance with Astellas Pharma Inc., enhancing its development and commercialization capabilities. The company's focus on muscle biology and innovative drug development positions it as a key player in the biotechnology sector, aiming to improve the lives of patients with muscle-related diseases.
What Products and Services Does CYTK Offer?
- Discovers and develops small molecule drug candidates.
- Focuses on muscle activators and inhibitors.
- Targets debilitating diseases related to muscle function.
- Conducts Phase I, II, and III clinical trials.
- Seeks regulatory approval for novel therapies.
- Commercializes approved drugs through strategic alliances.
- Researches and develops new treatments for heart failure, ALS, SMA, and HCM.
How Does CYTK Make Money?
- Develops and patents novel drug candidates.
- Conducts clinical trials to demonstrate safety and efficacy.
- Out-licenses or co-develops drugs with strategic partners.
- Generates revenue through milestone payments and royalties.
- Potentially commercializes drugs directly upon regulatory approval.
What Industry Does CYTK Operate In?
Cytokinetics operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The market for muscle-related disease treatments is expanding, driven by an aging population and increasing prevalence of conditions like heart failure and ALS. The competitive landscape includes companies like JAZZ: Jazz Pharmaceuticals plc and HALO: Halozyme Therapeutics, Inc., but Cytokinetics differentiates itself through its focus on muscle activators and inhibitors. The industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success and market access.
Who Are CYTK's Key Customers?
- Patients suffering from heart failure.
- Patients diagnosed with amyotrophic lateral sclerosis (ALS).
- Patients with spinal muscular atrophy (SMA).
- Patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
- Healthcare providers prescribing treatments for these conditions.
CYTK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, often a good sign for long-term prospects.
- The community buzz is largely positive, hinting at strong belief in their pipeline and potential catalysts.
- Market perception seems to be shifting towards recognizing the potential of their heart failure drug, driving optimism.
- Developments in the heart failure treatment space could provide tailwinds, lifting all boats including Cytokinetics.
Bear Case
- Insider activity, while positive, could be timed to news cycles rather than deep value assessment.
- Community sentiment can be fickle; hype doesn't always translate to real-world success or regulatory approval.
- Market perception can be easily swayed by competitors or negative trial data; risk is always present.
- Dependence on a single key drug candidate makes them vulnerable if trials falter or face unexpected hurdles.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CYTK Latest News
-
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
GlobeNewswire · Jun 8, 2026
-
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
Simply Wall St. · Jun 8, 2026
-
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Zacks · Jun 4, 2026
-
Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing
MT Newswires · Jun 2, 2026
CYTK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYTK.
Price Targets
Consensus target: $90.67
CYTK MoonshotScore
What does this score mean?
The MoonshotScore rates CYTK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing
Leadership: Robert I. Blum
CEO
Robert I. Blum has served as the President and Chief Executive Officer of Cytokinetics since 2007. His extensive background in the biopharmaceutical industry includes leadership roles at COR Therapeutics, where he was responsible for commercial and business development activities. He also held positions at SmithKline Beecham Pharmaceuticals. Blum holds a B.A. in Economics from the University of California, Berkeley, and an M.B.A. from Stanford University.
Track Record: Under Robert Blum's leadership, Cytokinetics has advanced multiple drug candidates into late-stage clinical development, including aficamten and omecamtiv mecarbil. He has overseen strategic alliances with companies like Astellas Pharma Inc., securing funding and expertise for drug development. Blum has also guided the company through significant milestones, including successful clinical trial results and regulatory submissions.
What Investors Ask About Cytokinetics, Incorporated (CYTK) — Healthcare
What does Cytokinetics, Incorporated do?
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company's primary focus is on developing small molecule drug candidates engineered to impact muscle function and contractility. Their pipeline includes treatments for heart failure, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). Cytokinetics operates through strategic alliances and internal research and development efforts to bring novel therapies to market.
What do analysts say about CYTK stock?
Analyst consensus on CYTK stock is generally positive, reflecting optimism about the company's late-stage clinical pipeline and potential for future revenue generation. Key valuation metrics include market capitalization and potential peak sales for lead drug candidates like aficamten. Growth considerations center on the successful completion of clinical trials and regulatory approvals. Analysts closely monitor clinical trial results and regulatory filings as key catalysts for stock performance. However, the inherent risks associated with biopharmaceutical development, including clinical trial failures and regulatory hurdles, are also considered.
What are the main risks for CYTK?
The main risks for Cytokinetics include the potential for clinical trial failures, regulatory setbacks, and competition from existing and emerging therapies. The company's high operating expenses and negative profit margin also pose financial risks. Dependence on strategic alliances for funding and expertise creates additional uncertainty. Patent expiration and generic competition could erode future revenue streams. Economic downturns and reduced healthcare spending could also negatively impact the company's performance. These risks are inherent in the biopharmaceutical industry and require careful monitoring.
What are the key factors to evaluate for CYTK?
Cytokinetics, Incorporated (CYTK) holds an AI score of 65/100 (moderate). Analysts target $90.67 (+29%). Not financial advice.
How frequently does CYTK data refresh on this page?
CYTK prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CYTK's recent stock price performance?
Cytokinetics, Incorporated (CYTK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Late-stage clinical pipeline with multiple drug candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYTK overvalued or undervalued right now?
Valuing Cytokinetics, Incorporated (CYTK) requires multiple metrics. Analysts target $90.67 (+29%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CYTK?
Before investing in Cytokinetics, Incorporated (CYTK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Future financial performance is subject to various risks and uncertainties.